Virogin aims to bring impactful therapeutic candidates to early clinical proof-of-concept for licensing and is committed to expand its pipeline through strategic collaborations. We welcome opportunities to collaborate with research institutes, biotech, and big pharma companies that wish to utilize our oncolytic virus platform and mRNA platform.

If you are interested in investment or partnership opportunities, please contact us at:

Contact Us

R&D and Headquarters, Canada

+1 (604) 720-8981

R&D Hub, China

+86 021-6990 0611

General Inquiries


Canada & US: